A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of AVEO Pharmaceuticals Inc (NASDAQ: AVEO) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on May 29, 2018 and NASDAQ: AVEO investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 05/25/2018 -- A deadline is coming up on May 29, 2018 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of AVEO Pharmaceuticals Inc (NASDAQ: AVEO) between May 16, 2012 and May 1, 2013.
Investors who purchased a significant amount of shares of AVEO Pharmaceuticals Inc (NASDAQ: AVEO) between May 16, 2012 and May 1, 2013, have certain options and should contact the Shareholders Foundation by email at email@example.com or call +1(858) 779 - 1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the AVEO Pharmaceuticals Inc (NASDAQ: AVEO) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/aveo-pharmaceuticals-inc-nasdaq-aveo-investor-securities-class-action-lawsuit-05092013
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is May 29, 2018. The class action administrator for this case is Epiq.
The lawsuit was originally filed in the U.S. District Court for the District of Massachusetts against AVEO Pharmaceuticals Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between January 3, 2012 and May 1, 2013.
According to the complaint the plaintiff alleges on behalf of all persons or entities who purchased or otherwise acquired securities of AVEO Pharmaceuticals Inc (NASDAQ: AVEO) between January 3, 2012 and May 1, 2013, that AVEO Pharmaceuticals Inc and certain of its officers and directors violated the Securities Exchange Act of 1934. More specifically, the plaintiff alleges that defendants allegedly conditioned investors to believe that AVEO Pharmaceuticals Inc's drug Tivopath or tivozanib, would receive approval from the U.S. Food and Drug Administration ("FDA") through a host of materially allegedly false and misleading statements regarding its Phase III ("TIVO-1") trial design and results.
Those who purchased shares of AVEO Pharmaceuticals Inc (NASDAQ: AVEO) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels